Insufficient treatment of severe depression in neuromyelitis optica spectrum disorder

Neurology: Neuroimmunology and NeuroInflammation

Volumn 3, Issue 6, 2016, Pages

  Chavarro, Velina S ^a   Mealy, Maureen A ^d   Simpson, Alexandra ^d   Lacheta, Anna ^a   Pache, Florence ^a,b   Ruprecht, Klemens ^b   Gold, Stefan M ^c,f   Paul, Friedemann ^a,b,e   Brandt, Alexander Ulrich ^a  

^a NeuroCure Clinical Research Center   (Germany)

^b Clinical and Experimental Multiple Sclerosis Research Center   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL EVALUATION; DEPRESSION; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; FATIGUE SEVERITY SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOOPTIC NEUROPATHY; NEUROPATHIC PAIN; OBSERVATIONAL STUDY; TREATMENT PLANNING;

EID: 85014646526     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000286     Document Type: Article

References (40)

1. Raskind MA. Diagnosis and treatment of depression comorbid with neurologic disorders. Am J Med 2008;121 (11 suppl 2):S28-S37.
2. Bakshi R, Shaikh ZA, Miletich RS, et al. Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler 2000;6:181-185.
3. Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS. Chronic pain-Associated depression: antecedent or consequence of chronic pain? A review. Clin J Pain 1997;13: 116-137.
4. Zekeridou A, Lennon VA, Zamvil SS, Slavin AJ. Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflammation 2015;2:e110. doi: 10.1212/NXI.0000000000000110.
5. Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 2014;176:149-164.
6. Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet 2012;379:1045-1055.
7. Kempton MJ. Structural neuroimaging studies in major depressive disorder. Arch Gen Psychiatry 2011;68:675-690.
8. Kim HJ, Paul F, Lana-Peixoto MA, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology 2015;84:1165-1173.
9. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012;9:14.
10. Pekcevik Y, Orman G, Lee IH, Meally MA, Levy M, Izbudak I. What do we know about brain contrast enhancement patterns in neuromyelitis optica? Clin Imaging 2016;40:573-580.
11. Moore P, Methley A, Pollard C, et al. Cognitive and psychiatric comorbidities in neuromyelitis optica. J Neurol Sci 2016;360:4-9.
12. Chanson JB, Zéphir H, Collongues N, et al. Evaluation of health-related quality of life, fatigue and depression in neuromyelitis optica. Eur J Neurol 2011;18:836-841.
13. Kawahara Y, Ikeda M, Deguchi K, et al. Cognitive and affective assessments of multiple sclerosis (MS) and neuromyelitis optica (NMO) patients utilizing computerized touch panel-type screening tests. Intern Med 2014;53: 2281-2290.
14. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States. Arch Neurol 2012;69:1176-1180.
15. Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler 2015;21:845-853.
16. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-189.
17. Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflammation 2015;2:e62. doi: 10.1212/NXI.0000000000000062.
18. Beck A, Steer R. Manual for the Beck Depression Inventory. San Antonio, TX: Psychological Corporation; 1993.
19. Beck A, Steer R, Ball R, Ranieri W. BDI Comparison of Beck Depression Inventories-IA and-II in psychiatric outpatients. J Pers Assess 1996;67:588-597.
20. Beck A, Steer R, Brown G. Beck Depression Inventory Manual, 2nd ed. Bloomington, IN: PsychCorp Pearson Clinical Assessment; 1996.
21. Arnau RC, Meagher MW, Norris MP, Bramson R. Psychometric evaluation of the Beck Depression Inventory-II with primary care medical patients. Health Psychol 2001; 20:112-119.
22. Sprinkle SD, Lurie D, Insko SL, et al. Criterion validity, severity cut scores, and test-retest reliability of the Beck Depression Inventory-II in a university counseling center sample. J Couns Psychol 2002;49:381-385.
23. Krupp L, LaRocca N, Muir-Nash J, et al. The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121-1123.
24. Flachenecker P, Kümpfel T, Kallmann B, et al. Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler 2002;8: 523-526.
25. Daut R, Cleeland C, Flanery R. Development of the Wisconsin Brief Pain Questionnaire to asses pain in cancer and other diseases. Pain 1983;17:197-210.
26. Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain 2004;5:133-137.
27. Zhao S, Mutch K, Elsone L, Nurmikko T, Jacob A. Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life. Mult Scler 2014;20: 1658-1661.
28. Freynhagen R, Baron R, Gockel U, Tölle TR. PainDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006; 22:1911-1920.
29. Kimbrough DJ, Fujihara K, Jacob A, et al. Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 2012;1:180-187.
30. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014;261:1-16.
31. Qian P, Lancia S, Alvarez E, Klawiter EC, Cross AH, Naismith RT. Association of neuromyelitis optica with severe and intractable pain. Arch Neurol 2012;69:1482-1487.
32. Kim SM, Go MJ, Sung JJ, Park KS, Lee KW. Painful tonic spasm in neuromyelitis optica. Arch Neurol 2012: 69:1026-1031.
33. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009; 122:S22-S32.
34. Jones JE, Hermann BP, Barry JJ, Gilliam F, Kanner AM, Meador KJ. Clinical assessment of axis I psychiatric morbidity in chronic epilepsy: a multicenter investigation. J Neuropsychiatry Clin Neurosci 2005;17:172-179.
35. Beck AT, Steer RA, Beck JS, Newman CF. Hopelessness, depression, suicidal ideation, and clinical diagnosis of depression. Suicide Life Threat Behav 1993;23: 139-145.
36. Beck T, Steer RA, Kovacs M, Garrison B. Hopelessness and eventual suicide: a 10-year prospective study of patients hospitalized with suicidal ideation. Am J Psychiatry 1985;142:559-563.
37. Von Korff M, Simon G. The relationship between pain and depression. Br J Psychiatry Suppl 1996: 101-108.
38. Reyes-Gibby CC, Aday LA, Anderson KO, Mendoza TR, Cleeland CS. Pain, depression, and fatigue in communitydwelling adults with and without a history of cancer. J Pain Symptom Manage 2006;32:118-128.
39. Visser MR, Smets EM. Fatigue, depression and quality of life in cancer patients: how are they related? Support Care Cancer 1998;6:101-108.
40. Dalgas U, Stenager E, Jakobsen J, et al. Fatigue, mood and quality of life improve in MS patients after progressive resistance training. Mult Scler 2010;16: 480-490.